Digestive and Liver Disease 2012-01-01

Adding banding ligation is effective as rescue therapy to prevent variceal rebleeding in haemodynamic non-responders to pharmacological therapy.

Antonio González, Salvador Augustin, Joan Dot, Mercedes Pérez, Monder Abu-Suboh, Alejandro Romero, Antoni Segarra, Josep Ramón Armengol, Rafael Esteban, Jaime Guardia, Joan Genescà

Index: Dig. Liver Dis. 44(1) , 55-60, (2012)

Full Text: HTML

Abstract

It is unknown which is the best therapy to treat haemodynamic non-responders to pharmacological therapy after variceal bleeding.To evaluate the efficacy of adding banding ligation to drugs to prevent variceal rebleeding in haemodynamic non-responders to drugs.Fifty-three cirrhotic patients with variceal bleeding underwent a hepatic venous pressure gradient (HVPG) measurement 5 days after the episode. Nadolol and nitrates were then titrated to maximum tolerated doses. A second HVPG was taken 14 days later. Responders (HVPG ≤12 mm Hg or ≥20% decrease from baseline) were maintained on drugs and non-responders had banding ligation added to drugs.Mean follow-up was 28 months. In 5 patients the second HVPG could not be performed because of early rebleeding. The remaining 48 patients were classified as responders (n=24) and non-responders (n=24), who had banding added. No baseline differences were observed between groups. Variceal rebleeding occurred in 12% of the 48 patients whose haemodynamic response was assessed. Responders on drug therapy presented a 16% rebleeding rate, whilst non-responders rescued with banding showed an 8% rebleeding rate. Rebleeding-related mortality was not different between groups.In a HVPG-guided strategy, adding banding ligation to drugs is an effective rescue strategy to prevent rebleeding in haemodynamic non-responders to drug therapy.Copyright © 2011 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.


Related Compounds

Related Articles:

In vitro and in vivo evaluation of novel osmotic pump tablets of isosorbide-5-mononitrate containing polyvinyl pyrrolidone (PVP) for controlled release.

2012-08-01

[Pharmazie 67(8) , 695-700, (2012)]

Vascular dysfunction in experimental diabetes is improved by pentaerithrityl tetranitrate but not isosorbide-5-mononitrate therapy.

2011-10-01

[Diabetes 60(10) , 2608-16, (2011)]

A randomized phase II study of irinotecan plus cisplatin versus irinotecan plus capecitabine with or without isosorbide-5-mononitrate in advanced non-small-cell lung cancer.

2012-11-01

[Ann. Oncol. 23(11) , 2925-30, (2012)]

Intravenous diuretic and vasodilator therapy reduce plasma brain natriuretic peptide levels in acute exacerbation of chronic obstructive pulmonary disease.

2013-01-01

[Respirology 17(4) , 715-20, (2012)]

In vitro dissolution and in vivo bioequivalence evaluation of two brands of isosorbide 5-mononitrate sustained release tablets.

2012-12-01

[Arzneimittelforschung 62(12) , 576-82, (2012)]

More Articles...